regardless of encouraging clinical evidence, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing substantial difficulty from pharmacy benefit managers. These organizations are frequently erecting obstacles to coverage, including high cost criteria and prior authorization that hinder patient a